AstraZeneca Pharma India Limited (ASTRAZEN.BO)
INR 8061.9
(2.24%)
INR 8061.9
(2.24%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.66 Billion INR | -7.59% |
| 2022 | 3.96 Billion INR | 14.78% |
| 2021 | 3.45 Billion INR | 8.36% |
| 2020 | 3.18 Billion INR | -6.84% |
| 2019 | 3.41 Billion INR | 31.0% |
| 2018 | 2.61 Billion INR | 22.19% |
| 2017 | 2.13 Billion INR | 10.9% |
| 2016 | 1.92 Billion INR | -21.46% |
| 2015 | 2.45 Billion INR | -5.98% |
| 2014 | 2.6 Billion INR | 6.9% |
| 2013 | 2.43 Billion INR | 18.24% |
| 2012 | 2.06 Billion INR | 32.59% |
| 2011 | 1.55 Billion INR | 20.65% |
| 2010 | 1.28 Billion INR | 44.37% |
| 2009 | 893.48 Million INR | -48.24% |
| 2008 | 1.72 Billion INR | 99.2% |
| 2007 | 866.51 Million INR | -11.69% |
| 2006 | 981.27 Million INR | 103.35% |
| 2005 | 482.54 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 FY | 3.66 Billion INR | -7.59% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 4.46 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 3.66 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 3.96 Billion INR | 14.78% |
| 2022 Q4 | 3.96 Billion INR | 0.0% |
| 2022 Q2 | 3.52 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 3.41 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 3.45 Billion INR | 0.0% |
| 2021 FY | 3.45 Billion INR | 8.36% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 3.15 Billion INR | 0.0% |
| 2020 Q4 | 3.18 Billion INR | 0.0% |
| 2020 FY | 3.18 Billion INR | -6.84% |
| 2019 FY | 3.41 Billion INR | 31.0% |
| 2019 Q2 | 3.16 Billion INR | 0.0% |
| 2019 Q4 | 3.41 Billion INR | 0.0% |
| 2018 Q4 | 2.61 Billion INR | 0.0% |
| 2018 Q2 | 2.23 Billion INR | 0.0% |
| 2018 FY | 2.61 Billion INR | 22.19% |
| 2017 FY | 2.13 Billion INR | 10.9% |
| 2017 Q2 | 2.19 Billion INR | 0.0% |
| 2017 Q4 | 2.13 Billion INR | 0.0% |
| 2016 Q2 | 2.25 Billion INR | 0.0% |
| 2016 FY | 1.92 Billion INR | -21.46% |
| 2016 Q4 | 1.92 Billion INR | 0.0% |
| 2015 Q2 | 2.36 Billion INR | 0.0% |
| 2015 FY | 2.45 Billion INR | -5.98% |
| 2015 Q4 | 2.45 Billion INR | 0.0% |
| 2014 Q2 | 2.51 Billion INR | 0.0% |
| 2014 FY | 2.6 Billion INR | 6.9% |
| 2014 Q4 | 2.6 Billion INR | 0.0% |
| 2013 Q2 | 2.6 Billion INR | 0.0% |
| 2013 FY | 2.43 Billion INR | 18.24% |
| 2013 Q4 | 2.43 Billion INR | 0.0% |
| 2012 Q4 | 2.06 Billion INR | 0.0% |
| 2012 FY | 2.06 Billion INR | 32.59% |
| 2011 Q4 | 1.55 Billion INR | 0.0% |
| 2011 FY | 1.55 Billion INR | 20.65% |
| 2010 FY | 1.28 Billion INR | 44.37% |
| 2009 FY | 893.48 Million INR | -48.24% |
| 2008 FY | 1.72 Billion INR | 99.2% |
| 2007 FY | 866.51 Million INR | -11.69% |
| 2006 FY | 981.27 Million INR | 103.35% |
| 2005 FY | 482.54 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 77.503% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 97.595% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 29.334% |
| Granules India Limited | 22.95 Billion INR | 84.05% |
| Indoco Remedies Limited | 10.34 Billion INR | 64.601% |
| Achyut Healthcare Limited | 2.01 Million INR | -181773.274% |
| Ajanta Pharma Limited | 10.71 Billion INR | 65.817% |
| Alkem Laboratories Limited | 48.6 Billion INR | 92.468% |
| Alpa Laboratories Limited | 307.12 Million INR | -1092.07% |
| Brooks Laboratories Limited | 248.6 Million INR | -1372.685% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 24.787% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -73.607% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 96.577% |
| Eris Lifesciences Limited | 38.26 Billion INR | 90.433% |
| FDC Limited | 3.7 Billion INR | 1.297% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 94.377% |
| Gufic Biosciences Limited | 5.59 Billion INR | 34.621% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -59.911% |
| Ipca Laboratories Limited | 33.74 Billion INR | 89.15% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -1133.694% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -23.107% |
| Lasa Supergenerics Limited | 541.92 Million INR | -575.575% |
| Laurus Labs Limited | 42.71 Billion INR | 91.429% |
| Lupin Limited | 96.23 Billion INR | 96.196% |
| Mankind Pharma Limited | 23.87 Billion INR | 84.665% |
| Medicamen Biotech Limited | 940.36 Million INR | -289.328% |
| Medico Remedies Limited | 438.24 Million INR | -735.404% |
| Megasoft Limited | 1.85 Billion INR | -97.562% |
| NATCO Pharma Limited | 10.53 Billion INR | 65.238% |
| Piramal Pharma Limited | 74 Billion INR | 95.053% |
| RPG Life Sciences Limited | 1.38 Billion INR | -165.259% |
| Sigachi Industries Limited | 2.53 Billion INR | -44.636% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.006% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -79.975% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -214.201% |
| Unichem Laboratories Limited | 8.06 Billion INR | 54.629% |
| Wanbury Limited | 3.15 Billion INR | -16.022% |
| Windlas Biotech Limited | 1.76 Billion INR | -107.699% |
| ZIM Laboratories Limited | 2.08 Billion INR | -75.95% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 94.9% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 5.954% |
| Divi's Laboratories Limited | 18.99 Billion INR | 80.721% |
| Hester Biosciences Limited | 3.59 Billion INR | -1.847% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -42.945% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -367.083% |
| Bal Pharma Limited | 2.51 Billion INR | -45.787% |
| Strides Pharma Science Limited | 37.68 Billion INR | 90.284% |
| Venus Remedies Limited | 1.39 Billion INR | -162.86% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 55.627% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 67.364% |
| Shilpa Medicare Limited | 12.93 Billion INR | 71.691% |
| Aarti Drugs Limited | 11.5 Billion INR | 68.175% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 42.153% |
| Suven Life Sciences Limited | 148.62 Million INR | -2363.386% |
| Ind-Swift Limited | 13.45 Billion INR | 72.786% |
| Valiant Laboratories Limited | 1.05 Billion INR | -245.956% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 65.81% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 74.115% |
| Themis Medicare Limited | 1.88 Billion INR | -93.965% |
| Hikal Limited | 12.99 Billion INR | 71.827% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 95.538% |
| Sequent Scientific Limited | 8.27 Billion INR | 55.753% |
| Novartis India Limited | 1.8 Billion INR | -103.271% |
| Wockhardt Limited | 39.87 Billion INR | 90.817% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 94.025% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -1167.701% |
| Neuland Laboratories Limited | 5.49 Billion INR | 33.417% |
| Morepen Laboratories Limited | 4.45 Billion INR | 17.908% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -468.598% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -85.25% |